Singapore: China's BeiGene, a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer, recently announced the establishment of its first current Good Manufacturing Practices (cGMP) biopharmaceutical manufacturing facility BioBAY in the Suzhou Industrial Park (SIP) in Suzhou, China.

The new 9,000 square meter (96,875 square feet) cGMP facility is expected to be completed by 2017. The facility expands company's production facilities and will supply materials for future clinical trials and subsequent commercial demand.

Suzhou BioBAY is strategically located less than one hour west of Shanghai and has become one of the premier science innovation hubs in China to over 400 domestic and international biotech and biopharma companies for research, development, and manufacturing.

Mr John V Oyler, CEO, BeiGene, said, "This new manufacturing facility is a key component to our strategic growth to become an integrated biopharma company and to accelerate and expand our development programs, which allows us to continue to focus on developing global best-in-class drugs for various cancer treatments and attract additional highly talented professionals to our organization,"

Mr Oyler added that the manufacturing site in BioBAY, positions Beigene to fully leverage the domestic regulatory pathway for our drugs in China and to build a global business. "Upon completion we will seek the necessary approvals to ensure our new site is fully compliant with regulatory procedures in all key global markets, including the United States, Europe and China," said the company's head of Regulatory Affairs, Mr Wendy Han.